Pharmacokinetics of nifedipine sustained-release tablets in healthy Chinese volunteers

Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 （5 μm, 4.6 mm ×150 mm） column and a mobile phase of methanol： 0.01 mol·L^-1ammonium acetate （60：40, V/V） were used to separate nifedipine, the detections was accuracy under atmosperic pressure electronic spray ionization （AP-ESI） mode and ion mass spectrum （m/z） of 314.9 [M＋H]^＋ for nifedipine, and 320.8 [M＋H]^＋ for lorazepam （Internal Standard, IS）. Results The linear range of nifedipine was 0.3 - 80 ng·mL^-1 （ r = 0.9997）, and the limit of quantitation （LOQ） was 0.3 ng·mL^-1. The nifedipine pharmacokinetic parameters after a single dose of 20 mg nifedipine sustained-release tablets test （T） or reference （R） were as the followings, t1/2 （6.73 ± 2.00） h and （7.04 ± 2.18） h, Tmax （4.28 ± 0.70） h and （4.48 ± 0.70） h, Cmax（39.66 ± 10.58） ng·mL^-1 and （40.19 ± 10.97） ng·mL^-1, AUC0-36 （391.63 ± 108.55） ng·mL^-1·h and （387.57 ± 121.51） ng·mL^-1·h, and AUC0-∞ （408.28 ± 121.16） ng·mL^-1·h and （406.15 ± 133.13） ng·mL^-1·h. The relative bioavailability of nifedipine sustained-release tablets （test） was （103.02 ± 13.93） %. Conclusion LC-MS method for the determination of concentrations of nifedipine in human plasma was sensitive and accurate, and could be used in nifedipine bioavailability and pharmacokinetic studies.

Preparation and <i>in Vitro</i>Drug Release Evaluation of Once-Daily Metformin Hydrochloride Sustained-Release Tablets

The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitro drug release rate of MHSRT and the commercial tablets Fortamet? made in the United States of America in water was fitted with zero order kinetic equation, and Ritger-Peppas kinetic equation in 0.1 M HCl and pH 6.8-phosphate buffer, respectively. The similarity factor f2 values of MHSRT in three different dissolution medium were 82, 80 and 74, respectively in comparison with imported Fortamet?, which were all greater than 50. The results of storage-stability showed that MHSRT were stable for at least 6 months under stress condition (40℃ ± 2℃, RH 75% ± 5%). Therefore, in this study, MHSRT were successfully prepared using optimized formulation technologies that meet mass produce. The in vitro release behavior of MHSRT was almost similar to that of imported Fortamet?.

Preparation and evaluation of sustained-release azithromycin tablets in vitro and in vivo

The objective of this study was to prepare azithromycin(AZI)sustained-release products in order to allow for a high dose to be administered,reduce gastrointestinal side-effects and increase the compliance of patients.AZI sustained-release tablets with different release performance(F-I:T_(100%)=3 h and F-II:T_(100%)=8 h in pH 6.0 phosphate buffer)were successfully prepared by wet granulation.The in vitro release rate and drug release mechanism were studied.The release rate of F-Iwas affected by dissolutionmedia with different pH,but not for F-II.HixsoneCrowellmodel was the best regression fitting model for F-I and F-II.Additionally,F-I and F-II both belonged to non-Fick diffusion.Oral pharmacokinetics of the two tablets and one AZI dispersible tablet as reference were studied in six healthy beagle dogs after oral administration.Compared with the reference,the C_(max) of F-I and F-II were decreased,and the T_(max) were prolonged,in that case which meet the requirement of sustained-release tablets.The relative bioavailability of F-I and F-II were 79.12%and 64.09%.T-test ofAUC_(0-144),and AUC_(0-∞) for F-I and F-II indicated there was no significant difference between F-I and F-II.These mean that the extended release rate did not induce different pharmacokinetics in vivo.

Clinical observation of Baitou Weng Decoction combined with mesalazine sustained-release tablets in treating heat-toxic and smoldering ulcerative colitis

Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and serum inflammatory factors.Methods: A total of 84 patients with ulcerative colitis were randomly divided into control group and treatment group, with 42 cases in each group. The control group was given mesalazine sustained-release tablets orally, while the treatment group was given Baitou Weng Decoction and mesalazine sustained-release tablets orally. The treatment period was 30 days and the patients were followed up for 3 months. After treatment, the clinical efficacy, quality of life, immune function and serum inflammatory factors of the two groups were observed.Results: The effective rate of treatment group (90.47%) was higher than that of control group (73.81%) (P<0.05);compared with before treatment, the scores of inflammatory bowel disease quality of life questionnaire scale in both groups were significantly improved (P<0.05), and the difference between the two groups was significant (P<0.05);after treatment, the plasma CD4+/CD8+ ratio and NK+ levels in both groups were significantly higher than those before treatment (P<0.05), and the treatment group was changed. The serum levels of tumor necrosis factor-α, interleukin-17 and interleukin-23 were significantly decreased in both groups after treatment (P<0.05), and the improvement was more significant in the treatment group (P<0.05). No significant adverse reactions were observed in the treatment group.Conclusions: Modified Baitou Weng Decoction combined with mesalazine in the treatment of heat-toxic and incandescent ulcerative colitis can significantly improve the clinical efficacy, improve the quality of life of patients, effectively regulate the expression level of serum inflammatory factors in ulcerative colitis patients, promote the recovery of patients' immune function, and have high drug safety.

Clinical observation on treatment of cancer pain with TCM oriented drugs combined with oxycodone sustained-release tablets and nimesulide sustained-release tablets

Objective： To study the effect of the transdermal preparation of traditional Chinese medicine in treating cancer pain. Methods： From October 2016 to January 2018, 126 patients with cancer pain were enrolled and divided into 4 groups, 39 patients in group A （directed TCM permeation）, 26 patients in group B （oxycodone sustained-release tablets）, 32 patients in group C （Chinese medicine directed drug penetration ＋ oxycodone sustained-release tablets）, and 29 patients group D （Chinese medicine directed drug penetration ＋ oxycodone sustained-release tablets ＋ nimesulide sustained release tablets）, according to KPS scores. Results： Transdermal preparations of traditional Chinese medicine can significantly alleviate cancer pain. For the treatment of moderate to severe cancer pain, the Chinese medicine transdermal preparation can reduce the dosage of oxycodone sustained-release tablets. At the same time, the patient＇s KPS and NRS scores were significantly reduced. Moreover, the transdermal preparation of traditional Chinese medicine has a better therapeutic effect on visceral pain. Conclusion： The traditional Chinese medicine tra_nsdermal preparation combined with western medicine for the treatment of cancer pain may be a new method for the treatment of cancer pain.

Pharmacokinetic Study on Lovastatin Sustained-release Tablet and Sustained-release Capsule in Begal Dogs

This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagle dog plasma. Pharmacokinetic findings were compared among three preparation(lovastatin sustained-release tablet,T p; sustained-release capsule,T J and conventional capsule). Our results showed that the pharmacokinetic parameters in 6 dogs after single-dose oral administration of three perparations were calculated. T max, C max and MRT revealed significant difference (P<0.05). Relative bioavailability was 111.5±16.9 % (T P) and 110.4%±9.6 % (T J). The pharmacokinetic parameters in the 6 dogs after multiple-dose oral administration of three perparations, T max, C max MRT and DF had significant difference (P<0.05); C av , C min and AUC 0-24 h displayed no significant difference (P>0.05). It is concluded that the lovastatin sustained-release tablet and sustained-release capsule are able to maintain a sustained-release for 24 h.

Simultaneous Analysis of Indapamide and Related Impurities in Sustained-Release Tablets by a Single-Run HPLC-PDA Method

The contents of indapamide and related impurities in generic indapamide sustained-release tablets were simultaneously detected by a single-run high performance liquid chromatography equipped with photodiode array detector(HPLC-PDA)method for the quality control in this paper.The results showed the method had a good selectivity and was validated through linearity,limits of detection and quantification,recovery,and precision.The linear ranges of indapamide,2-methyl-1-nitroso-2,3-dihydro-1H-indole(impurity A,ImA),4-chloro-N-(2-methyl-1H-indol-1-yl)-3-sulphamoyl-benzamide(impurity B,ImB)and 4-chloro-3-sulfamoylbenzoic acid(impurity 1,Im1)were 0.028-1.80μg/mL(R=0.99995),0.060-1.20μg/mL(R=0.9996),0.0324-1.20μg/mL(R=0.99985)and 0.060-1.20μg/mL(R=0.9997)with detection limits of 0.0093,0.012,0.012 and 0.006μg/mL,respectively.ImA and Im1 were not detectable in the generic drug.The content of indapamide was 96.7%of the labeled amount with a relative standard deviation(RSD)of 1.30%,and the percentage of ImB relative to the labeled amounts of indapamide was 0.106%with an RSD of 1.82%.The content of other unspecified impurities all met the reference quality standards.The results provided references for the quality control and the quality standard study of generic indapamide sustained-release tablets.

Qualitative and quantitative analysis of HPLC fingerprint of Wuji gastric floating sustained-release tablets

A qualitative and quantitative test method of fingerprint of Wuji gastric floating sustained-release tablets was established. High performance liquid chromatography （HPLC） was adopted, using Agilent ZORBAX SB-C18 column （250 mm×4.6 mm, 5 μm） as the chromatographic column, and acetonitrile-0.05 mol/L potassium dihydrogen phosphate solution as the mobile phase in a gradient elution with the flow rate of 1.0 mL/min. Sample solution （10 μL） was injected and was tested at the wavelength of 225 nm for 75 min at the column temperature of 30 ℃, Fingerprint similarity software （2004A version） was used to conduct data analysis. A total of 11 batches of Wuji gastric floating sustained-release tablets were tested and analyzed with HPLC fingerprint. Seventeen common peaks were found and the similarity of the 11 batches of agents was greater than 0.9, indicating that the production process of the agent is stable and feasible. The method is operable and could effectively control the quality of Wuji gastric floating sustained-release tablets.

艾地苯醌联合多巴丝肼片及吡贝地尓缓释片治疗老年PD伴抑郁的疗效及对患者炎症因子、神经细胞因子水平的影响

目的观察艾地苯醌联合多巴丝肼片及吡贝地尓缓释片治疗老年帕金森病(PD)伴抑郁的疗效,并探讨其对患者炎症因子、神经细胞因子水平的影响。方法选择2020年7月至2022年7月商洛市中心医院收治的460例老年PD伴抑郁患者进行研究,根据随机数表法分为观察组和对照组各230例。对照组患者采用多巴丝肼片及吡贝地尓缓释片治疗,观察组患者在对照组治疗的基础上联合艾地苯醌治疗,两组患者均连续治疗3个月。比较两组患者治疗3个月后的临床疗效,以及治疗前、治疗3个月后的血清C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-1(IL-1)、神经生长因子(NGF)、脑源性神经营养因子(BDNF)水平、蒙特利尔认知评估量表(MoCA)评分(北京版)、简易精神状态检查量表(MMSE)评分、焦虑自评量表(SAS)和抑郁自评量表(SDS)评分,并记录两组患者在治疗期间不良反应的发生情况。结果观察组患者治疗后的总有效率为95.22%,明显高于对照组的90.00%,差异有统计学意义(P<0.05);治疗后,观察组患者的CRP、TNF-α、IL-6、IL-1水平分别为(5.16±0.52)mg/L、(34.93±1.60)mg/L、(42.81±5.54)pg/L、(42.06±4.59)pg/L,明显低于对照组的(7.27±1.12)mg/L、(51.78±2.83)mg/L、(64.04±5.40)pg/L、(62.86±7.91)pg/L,血清NGF、BDNF水平分别为(13.22±1.83)ng/L、(18.70±2.15)ng/L,明显高于对照组的(9.75±1.20)ng/L、(12.46±1.80)ng/L,差异均有统计学意义(P<0.05);治疗后,观察组患者的MoCA、MMSE评分分别为(24.72±2.25)分、(25.75±2.50)分,明显高于对照组的(21.30±2.17)分、(22.62±2.31)分,SAS、SDS评分分别为(43.37±3.06)分、(43.70±2.14)分,明显低于对照组的(55.12±4.92)分、(55.18±2.09)分,差异均有统计学意义(P<0.05);观察组和对照组患者的不良反应发生率分别为7.27%、14.55%,差异无统计学意义(P>0.05)。结论艾地苯醌联合多巴丝肼片及吡贝地尓缓释片治疗老年PD伴抑郁能降低患者的CRP、TNF-α、IL-6、IL-1表达水平,提高NGF、BDNF水平,临床应用效果显著。

吡贝地尔缓释片联合盐酸多奈哌齐治疗对帕金森病患者认知功能及血清sLAG3、RANTES水平的影响

目的研究吡贝地尔缓释片联合盐酸多奈哌齐治疗对帕金森病(PD)患者认知功能及血清可溶性淋巴细胞活化基因3(sLAG3)、活化T细胞趋化因子(RANTES)水平的影响。方法选取2020年3月至2022年10月南阳市中心医院神经内科收治的134例PD患者为研究对象,采用随机数表法分为对照组和联合组各67例。对照组患者采用盐酸多奈哌齐治疗,联合组患者采用吡贝地尔缓释片联合盐酸多奈哌齐治疗,均治疗3个月。治疗后比较两组患者的临床疗效,以及治疗前、治疗1个月、3个月后的帕金森综合评分量表-Ⅲ(UPDRS-Ⅲ)、智力状态检查量表(MMSE)、帕金森病睡眠障碍量表(PDSS)评分、血清神经递质[脑源性神经营养因子(BDNF)、5-羟色胺(5-HT)、神经元特异性烯醇化酶(NSE)、去甲肾上腺素(NE)]和血清白介素-6(IL-6)、白介素-1β(IL-1β)、sLAG3、RANTES水平,同时比较两组患者治疗期间的不良反应发生情况。结果联合组患者的临床治疗总有效率为94.03%,明显高于对照组的82.09%,差异有统计学意义(P<0.05);治疗1个月、3个月后,联合组患者的UPDRS-Ⅲ评分明显低于对照组,MMSE、PDSS评分明显高于对照组,差异均有统计学意义(P<0.05);治疗1个月、3个月后,联合组患者的血清BDNF、5-HT、NE水平明显高于对照组,NSE水平明显低于对照组,差异均有统计学意义(P<0.05);治疗1个月、3个月后,联合组患者的血清IL-6、IL-1β、sLAG3、RANTES水平明显低于对照组,差异均有统计学意义(P<0.05);治疗期间联合组患者的不良反应总发生率为5.79%,略高于对照组的1.49%,但差异无统计学意义(P>0.05)。结论吡贝地尔缓释片联合盐酸多奈哌齐治疗PD可有效改善患者的神经功能、运动功能、认知功能、睡眠质量,提高临床疗效,且安全性较高。

多巴丝肼联合吡贝地尔缓释片治疗帕金森病的疗效观察

目的探讨多巴丝肼联合吡贝地尔缓释片治疗帕金森病的疗效。方法从我院在2017年5月至2019年4月期间收治的帕金森病患者中抽选出60例患者纳入本次研究中,按照不同的治疗方式对患者进行分组处理,共分为观察组与对照组两个组,每组各有30例患者,给予对照组多巴丝肼治疗,给予观察组多巴丝肼联合吡贝地尔缓释片进行治疗,观察比较两组患者在经过不同治疗方式后的疗效与不良反应的发生情况。结果观察组患者治疗后的总有效率要明显比对照组高,经过计算,两组患者对比所产生的差异发生统计学意义(P<0.05),观察组患者在治疗后,不良反应的实际发生率要比对照组低,两组患者对比所产生的差异发生统计学意义(P<0.05)。结论在治疗帕金森病患者时,除了给予患者多巴丝肼进行治疗外,联合使用吡贝地尔缓释片进行治疗,能够有效的缓解患者的临床症状,提升治疗效果,降低不良反应的发生,临床效果限制,值得临床推广。

多巴丝肼联合吡贝地尔缓释片治疗帕金森病对照研究

目的探究多巴丝肼联合吡贝地尔缓释片治疗帕金森病患者的临床疗效和安全性.方法将140例帕金森病患者按随机数字表法分为两组,每组70例,对照组予以多巴丝肼治疗,观察组予以多巴丝肼联合吡贝地尔缓释片治疗,观察6个月.采用帕金森氏病综合评分量表及Webster量表评估临床疗效,随时记录治疗过程中出现的不良反应,同时检测两组血清白细胞介素1β、胱抑素C水平变化.结果治疗后观察组总有效率(92.9%)显著高于对照组(80.0%)(P<0.05);帕金森氏病综合评分量表总分、各项目评分及Webster量表评分均显著低于对照组(P<0.01);血清白细胞介素1β、胱抑素C水平显著低于对照组(P<0.01);不良反应发生率(4.3%)显著低于对照组(17.1%)(P<0.05).结论多巴丝肼联合吡贝地尔缓释片治疗帕金森病具有协同增效作用,可改善患者病情,降低血清白细胞介素1β、胱抑素C水平,提高临床疗效,且安全性较高.

吡贝地尔缓释片联合多巴丝肼片对早期帕金森病患者运动相关功能及脑神经递质水平的影响

目的:探讨吡贝地尔缓释片联合多巴丝肼片对早期帕金森病患者运动相关功能及脑神经递质水平的影响。方法:选择86例早期帕金森病患者为研究对象,随机分为试验组44例、对照组42例。对照组给予多巴丝肼片治疗,试验组给予吡贝地尔缓释片联合多巴丝肼片治疗。治疗6个月,比较两组临床疗效、帕金森病综合评分量表(UPDRS)评分、脑神经递质水平、不良反应发生率。结果:试验组有效率、5-羟色胺、多巴胺水平高于对照组(P<0.05)、UPDRS总分,脑γ-氨基丁酸水平低于对照组(P<0.05);两组恶心呕吐等不良反应比较差异无统计学意义(P>0.05)。结论:联合疗法有助于改善帕金森病患者运动相关功能状态,可提高临床疗效。

美多芭联合吡贝地尔缓释片治疗帕金森病的临床观察

目的观察美多芭联合吡贝地尔缓释片在治疗帕金森病中的临床效果。方法选取2018年9月至2020年3月就诊本院的帕金森病Hoehn-Yahr分级Ⅲ级以下的患者64例,随机分为研究组、对照组。对照组予美多芭治疗,研究组在上述治疗上加吡贝地尔缓释片,90 d为1个疗程。观察两组治疗前、后临床疗效、UPDRS评分中日常生活能力及运动检查分值变化、不良反应。结果研究组临床疗效总有效率90.63%,高于对照组71.88%(P<0.05);研究组UPDRS评分低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论美多芭联合吡贝地尔缓释片治疗帕金森病临床疗效确切,适合临床应用。

多巴胺受体激动剂治疗小儿多动症的临床疗效及安全性分析

目的分析多巴胺受体激动剂治疗小儿多动症的临床疗效和安全性。方法130例多动症患儿,随机分为对照组和观察组,每组65例。对照组患儿给予常规多动症药物治疗,观察组患儿给予多巴胺受体激动剂治疗。比较两组患儿Conners儿童行为量表评分、临床疗效及不良反应发生情况。结果观察组患儿学习行为、心身行为、冲动行为、品行行为评分和多动指数分别为(1.08±0.42)、(0.23±0.20)、(0.82±0.39)、(0.83±0.27)、(1.04±0.39)分,均显著低于对照组的(1.71±0.60)、(0.72±0.51)、(1.81±0.86)、(1.42±0.53)、(2.03±0.75)分,差异有统计学意义(P<0.05)。观察组治疗总有效率92.31%高于对照组的76.92%,差异有统计学意义(P<0.05)。观察组不良反应发生率6.15%显著低于对照组的18.46%,差异有统计学意义(P<0.05)。结论对小儿多动症应用多巴胺受体激动剂治疗可以明显提升临床疗效,且总体安全性较好,是一种比较理想的治疗药物,值得临床推广应用。

多巴丝肼片与吡贝地尔缓释片联用致体位性低血压1例

1例75岁高血压、糖尿病、帕金森病患者,入院后为抗帕金森病给予多巴丝肼片(62.5 mg,bid)和吡贝地尔缓释片(50 mg,bid)。用药3日后出现体位性低血压,将多巴丝肼片减量为62.5 mg,qd,1日后好转,续观3日后体位性低血压未再出现。

吡贝地尔缓释片释放度检测方法学研究

目的建立测定吡贝地尔缓释片体外释放度的方法。方法采用溶出度浆法的装置进行体外释放实验,以0.1 mol/L盐酸溶液1 000 m L释放介质,转速为50 r/min,温度为（37±0.5）℃,含量检测方法为高效液相色谱法（HPLC）。结果吡贝地尔在6.87-89.34μg/m L（r=1.000）范围内呈良好的线性关系;平均回收率为100.72%（RSD=0.6%）,3批产品在2、4 h和8 h的平均累积释药量分别为32.7%、52.7%和80.0%,符合2010年版《中国药典》缓释制剂的指导原则。结论溶出度浆法检测准确、可靠、灵敏,可用于吡贝地尔缓释片释放度的测定。

多巴胺受体激动剂治疗小儿多动症的临床疗效

目的 探讨多巴胺受体激动剂治疗小儿多动症的临床疗效。方法 80例小儿多动症患儿,随机分为观察组和对照组,各40例。对照组患儿给予盐酸哌甲酯控释片(商品名:专注达)治疗,观察组患儿给予多巴胺受体激动剂吡贝地尔缓释片治疗。对比两组患儿治疗效果、行为问题评分、多巴胺水平、多动指数、不良反应发生率。结果 观察组患儿治疗总有效率90.0%明显高于对照组的70.0%,差异有统计学意义(P<0.05)。观察组患儿心理问题、品行问题及学习问题评分分别为(0.78±0.21)、(0.62±0.18)、(0.75±0.26)分,低于对照组的(1.34±0.57)、(1.13±0.39)、(1.33±0.62)分,差异具有统计学意义(P<0.05)。观察组患儿多巴胺水平明显高于对照组,多动指数明显低于对照组,差异有统计学意义(P<0.05)。观察组患儿不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论 对多动症患儿采用多巴胺受体激动剂进行治疗具有更好的效果,能够显著改善患儿的行为症状、多动指数等,同时还能够降低患儿不良反应的发生率。

醒脑静注射液联合吡贝地尔缓释片治疗急性脑梗死昏迷的临床效果

目的探讨醒脑静注射液联合吡贝地尔缓释片治疗急性脑梗死昏迷患者的临床效果。方法选取我院2017年6月至2018年10月收治的急性脑梗死昏迷患者120例,采用随机数字表法将其分为对照组与研究组,各60例。对照组于常规干预基础上给予吡贝地尔缓释片,研究组于对照组基础上给予醒脑静注射液,两组患者均治疗14d。比较两组治疗前、后的GCS、NIHSS评分、血清因子[干扰素-γ(IFN-γ)、肿瘤坏死因子-α(TNF-α)]水平及不良反应发生率。结果治疗后,两组患者的GCS较治疗前升高,NIHSS较治疗前降低,且研究组GCS及NIHSS评分均优于对照组(P<0.05)。治疗后,两组患者的IFN-γ及TNF-α水平均低于治疗前,且研究组低于对照组(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论醒脑静注射液联合吡贝地尔缓释片治疗急性脑梗死昏迷患者的效果显著,可有效缓解患者的昏迷状态,恢复其神经功能,且不会增加不良反应,值得临床推广应用。

HPLC法测定吡贝地尔缓释片的释放度

目的：建立测定吡贝地尔缓释片释放度的方法。方法：采用HPLC法，色谱柱为ZORBAXEclipseXDB—C18（250mm×4．6mm，5μm），流动相为0．01mol·L-1庚烷磺酸钠的0．015mol·L-1磷酸二氢钾溶液（用磷酸调节pH值至3．3）-乙腈（73：27），流速为1．0mL·min-1，检测波长为286nm。结果：吡贝地尔在0．00996—0．05974mg·mL-1范围内呈良好线性关系（r=1），平均回收率为99．8％，RSD为0．28％。结论：该法灵敏度高、结果准确、重现性好，适用于吡贝地尔缓释片的释放度测定。